EyePoint shares are trading lower after the company announced topline results from LUGANO, the first pivotal Phase 3 clinical trial for DURAVYU. The primary endpoint of change from baseline in best corrected visual acuity versus 2 mg aflibercept o...

EyePoint, Inc.

EyePoint, Inc.

EYPT

0.00
EyePoint shares are trading lower after the company announced topline results from LUGANO, the first pivotal Phase 3 clinical trial for DURAVYU. The primary endpoint of change from baseline in best corrected visual acuity versus 2 mg aflibercept on-label control was not achieved in the full dataset.
This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.